#Biopharmaceuticals #Neuroscience #HealthcareInnovation
www.benzinga.com
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Xenon Pharmaceuticals (NASDAQ:XENE)
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.
#GeneticMedicine #Biopharmaceuticals #Leadership
www.benzinga.com
ElevateBio Appoints Christopher Murphy as Chief Executive Officer and Member of the Board of Directors
WALTHAM, Mass. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced the appointment of Christopher Murphy as Chief Executive Officer (CEO) and member of its Board of Directors.
#Pelthos #Xeglyze #Biopharmaceuticals
www.benzinga.com
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)
Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older
DURHAM, N.
#Pelthos #Xeglyze #Biopharmaceuticals
www.benzinga.com
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)
Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older
DURHAM, N.
#Pelthos #Xeglyze #Biopharmaceuticals
www.benzinga.com
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)
Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older
DURHAM, N.
#Biopharmaceuticals #GeneticDiseases #HealthcareConference
www.benzinga.com
BridgeBio to Participate in the J.P. Morgan Healthcare Conference - BridgeBio Pharma (NASDAQ:BBIO)
PALO ALTO, Calif. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.
#Biopharmaceuticals #LiverDisease #FDAApproval
www.benzinga.com
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - Altimmune (NASDAQ:ALT)
GAITHERSBURG, Md. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.
#biopharmaceuticals #cancerresearch #clinicaltrials
www.nasdaq.com
HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer
(RTTNews) - HUTCHMED (China) Ltd (HCM, HCM. L,0013. HK), a commercial-stage, biopharmaceutical company, announced on Monday that it has commenced the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib combined with camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma or PDAC in China.
